Fuat Bicer MD, PhD
@fuatbcr#Academic #GUOncologist @OhioStateMedOnc #CancerVaccine, #IO, @CureCancer. Curing cancer needs teamwork, Being scientist revealed my ignorance to Universe-FB
Similar User
@AJangMD
@arafflemd
@AmandaNizamMD
@KMittalmd
@ADESAIONCMD
@ronanhsieh
@DrKarieRuncie
@koshkin85
@DMakrakisMD
@bergsa83
@MikeSerzanMD
@YuWeiChenMD
@DrTylerStewart
@HasanovLab
@jordanciuro
We have more #Buckeye presentations today at #NCSAUA24! Hear from faculty members @AshabsighMd, @shawndason, @MSLee_MD, @Sood11, and @eric_facs, as well as @OhioStateMed and #UroScholar student @ap_mistry! @NCSAUA @OSUWexMed @OSUCCC_James
Critical TNM PCa: N1 indicates regional LNs>>Stage IVA. PCa staging includes only N1; there are no N2 or N3 M1a represents metastasis to non-regional LNs>>Stage IVB. Bladder: N3>> non-regional LNs (common iliac)>> Stage IIIB. M1a> LNs beyond common iliac>> Stage IVA @UpToDate
Day 3 #ESMO24 highlights: 1. #KN522: Update TNBC 2. #NIAGARA: resectable MIBC @tompowles1 @PGrivasMDPhD 3. #CONTACT02: Update mCRPC @neerajaiims 4. #NICHE2: dMMR Colon Ca @MyriamChalabi 1/5 #OncTwitter @myESMO @OncoAlert #bcsm #gism #MedTwitter
Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma | New England Journal of Medicine nejm.org/doi/full/10.10…
Neoadjuvant immunotherapy in locally advanced MMR-deficient colon cancer: #ESMO24 🔎3-year disease-free survival from NICHE-2 👉💯% DFS 👉all MRD pts cleared ctDNA 🧐Impressive results, ctDNA may be helpful to select for organ preservation @myESMO #ESMOAmbassadors
Adjuvant Pembrolizumab in MIBC #354 pts to pembro #348 to observation. #DFS was 44.8 mon. #Median DFS was 29.6 months with pembro and 14.2 months with observation (HR 0.73; P=0.003). nejm.org/doi/full/10.10…
Incidentally, this is the fifth article to be published in @nejm from a trial I oversaw or co-led while I was working @NCICTEP_ClinRes…. (If you aren’t following me now, shouldn’t you be?)
Proud to be part of the team that brought together the #AMBASSADOR trial from @ALLIANCE_org and @NCICTEP_ClinRes! We got this into @myESMO & @NEJM! Incredible work led by @apolo_andrea of @NCIResearchCtr Article here: nejm.org/doi/full/10.10…
Preliminary efficacy and safety of Disitamab Vedotin (DV) + Pembrolizumab (P) in Tx-Naive HER2-Expressing La/mUC. Promising ORR: 75% in overall population. Manageable safety profile observed. @MattGalsky Excited to be part of PIII trial. #ESMO24 @oncoalert @myESMO #cancer…
First-ever neoadjuvant IO trial shows OS benefit in MIBC! Durvalumab + Chemo improved EFS and OS in muscle-invasive bladder cancer. Significant step forward in #BladderCancer treatment! @tompowles1 @Uromigos #ESMO24 @oncoalert @myESMO #cancer #oncology @DrChoueiri…
Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma | New England Journal of Medicine nejm.org/doi/full/10.10…
Two of our @OSUCCC_James #genitourinary medical oncology specialists--Drs. @lingbin_meng & @fuatbcr-- with Dr. Claire Verschraegen go.osu.edu/medoncteam
Thanks to @OSUHematology @OSUCCC_James for the warm welcome to the Division. Honored to be part of an outstanding group of professionals! Thanks to Dr Verschraegen for her commitment and terrific job in the last 7 years, thrilled to work all together! @OhioState
Scenes from our welcome breakfast for @ChristianRolfo, including a rare group shot! @OSUCCC_James
Drs. Verschraegen, Bicer, Rolfo & Risch & our division administrator, Kristina Ambrosio, at the new faculty welcome event.
1/ Results from #LITESPARK-005 are out @NEJM! The phase 3 trial that led to HIF-2 inhibitor Belzutifan (BEL) @US_FDA approval Dec 2023 in pretreated pts w/ #ccRCC. Presentation #ESMO24 @myEsmo Check it out: nejm.org/doi/full/10.10…
Great to see you last night Fuat!
Good luck to all of our riders tomorrow! 💪🏼🚴♂️🚴♀️🚴🏿
We're ready to kick off @Pelotonia 16th Ride Weekend at today's Opening Ceremony. 🚲🔬🎉 Stop by our tent today in the Arena District, and pick up some great items and info while supporting the ultimate goal of #EndingCancer through @OhioState research.
United States Trends
- 1. #UFC309 121 B posts
- 2. Bo Nickal 5.986 posts
- 3. #MissUniverse 388 B posts
- 4. Tatum 24 B posts
- 5. Tennessee 50,8 B posts
- 6. Beck 20,3 B posts
- 7. Oregon 32,7 B posts
- 8. Paul Craig 3.396 posts
- 9. #GoDawgs 10,2 B posts
- 10. Georgia 95,1 B posts
- 11. Dinamarca 32,7 B posts
- 12. Nigeria 263 B posts
- 13. Locke N/A
- 14. Wisconsin 47,6 B posts
- 15. Venezuela 215 B posts
- 16. Dan Lanning 1.241 posts
- 17. gracie 19,8 B posts
- 18. Heupel 1.566 posts
- 19. Mike Johnson 43 B posts
- 20. Denmark 31,7 B posts
Who to follow
-
Albert Jang, MD
@AJangMD -
Alex Chehrazi-Raffle, MD
@arafflemd -
Amanda Nizam, MD
@AmandaNizamMD -
KMittaloncMD
@KMittalmd -
Arpita Desai
@ADESAIONCMD -
Ronan Hsieh, MD, MS
@ronanhsieh -
Karie Runcie, MD
@DrKarieRuncie -
Vadim Koshkin MD
@koshkin85 -
Dimitrios (Dimitri) Makrakis
@DMakrakisMD -
Stephanie Berg
@bergsa83 -
Michael Serzan, MD
@MikeSerzanMD -
Yu-Wei Chen, MD, MS
@YuWeiChenMD -
DrTylerStewart
@DrTylerStewart -
Elshad Hasanov, MD, PhD
@HasanovLab -
Jordan Ciuro, MD
@jordanciuro
Something went wrong.
Something went wrong.